Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance.

[This corrects the article DOI: 10.21037/tlcr-22-318.]. 2022 Translational Lung Cancer Research. All rights reserved.

This article (1) titled “Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance” (doi: 10.21037/tlcr-22-318), unfortunately contains errors in Figure 2D and Figure 7A. The bands of KEAP1 in Figure 2D should be 13, and “Osimertinib” in Figure 7A should be “Gefitinib”. The correct Figure 2 and Figure 7 can be found below.

Correct Figure 2:

Correct Figure 7:

The authors apologize for the oversight.

Click here to view the updated version of the article.